Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 555-564

  Dunlop, William ^a   Iqbal, Itrat ^a   Khan, Ifty ^b   Ouwens, Mario ^c   Heron, Louise ^d  

^a Mundipharma International Limited   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAPI GROUP   (Netherlands)

^d ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Cost utility analysis; Cost effectiveness analysis; Modified release prednisone; Morning stiffness; Quality of life; Rheumatoid arthritis

Indexed keywords

PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; UNITED KINGDOM;

EID: 84886861773     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S47867     Document Type: Article

References (39)

1. Lundkvist J, Kastang F, Kobelt G. The burden of rhematoid arthritis and access to treatments: health burden and costs. Eur J Health Econ. 2008;8(2):49-60.
2. Grassi W, De AR, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27(1):18-24.
3. Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics. 2010;28(6):477-487.
4. Cutolo M. How should morning function in rheumatoid arthritis be assessed? Bibliographic study of current assessment. Scand J Rheumatol Suppl. 2011;125:17-22.
5. Sierakowski S, Cutolo M. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl. 2011;125:1-5.
6. da Silva JA, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol Suppl. 2011;125:6-11.
7. Khan NA, Yazici Y, Calvo-Alen J, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol. 2009;36(11):2435-2442.
8. American Autoimmune Related Disease Association. The cost burden of autoimmune disease: the lastest front in the war on spending. National Institute of Health Progress in Autoimmune Disease Research Report, 2011. Available from: http://www.aarda.org/pdf/cbad.pdf. Accessed July 27,2013.
9. National Institute for and Clinical Excellence. Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE Clinical Guidelines, 2009. Available from: http://publications.nice.org.uk/rheumatoid-arthritis-cg79. Accessed July 27,2013.
10. National Audit Office. Services for people with rhematoid arthritis. Report by the comptroller and auditor general 823,Session HC823. 2009. Available from: http://www.nao.org.uk/wp-content/uploads/2009/07/0809823.pdf.Accessed July 27, 2013.
11. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275-1280.
12. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997;56(1):27-31.
13. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205-214.
14. Alten R. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8(2):123-133.
15. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72(2):204-210.
16. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-292.
17. Mundipharma International. Data on file: IMS SF-6D results. 2011.
18. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis. 2008;67(2): 238-243.
19. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2011;14(6):907-920.
20. Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci. 2005;46(11):4016-4023.
21. National Insititute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. Available from: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed July 27, 2013.
22. Iqbal I, Dasgupta B, Taylor P, Heron L, Pilling C. Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritis. J Med Econ. 2012;15(6):1192-2000.
23. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol. 2011;2011:845496.
24. Mundipharma International. Data on file: transition probabilities for CAPRA-1. 2011.
25. Murphy K, Spence S, McIntosh C, Connor-Gorber S. Health state descriptions for canadians: musculoskeletal diseases. Statistics Canada. 2006;82:1-38.
26. Yazici Y, Pincus T, Kautiainen H, Sokka T. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J Rheumatol. 2004;31(9):1723-1726.
27. National Rheumatoid Arthritis Society. Living with RA: case studies. Available from: http://www.nras.org.uk/about_rheumatoid_arthritis/living_with_rheumatoid_arthritis/default.aspx. Accessed July 27, 2013.
28. EuroQol Group http://www.euroqol.org/about-eq-5d/eq-5d-nomenclature.html. Accessed 15, August 2013.
29. British National Formulary No 63. BNF Prednisone. 2012. Available from: http://www.medicinescomplete.com/mc/bnf/current/213856.htm. Accessed July 27, 2013.
30. Mundipharma International. Data on file: Drug related TEAE. 2006.
31. Pfeiffer B, Krenzer S, Dockhorn R, et al. Impact of modified-release prednisone on functional ability in patients with RA. Rheumatol Int. 2013;33(6):1447-1454.
32. Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford). 2012;51(4):21-26.
33. Boers M, Buttgereit F. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2013;52(8):1435-1437.
34. Curtis L. Personal and Social Services Research Unit. Unit costs of health and social care. Available from: http://www.pssru.ac.uk/. Accessed July 27, 2012.
35. Ware JE. SF-36 Health Survey Update 2012. Available from: http://www.sf-36.org/tools/sf36.shtml. Accessed July 27, 2013.
36. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008;35(4): 592-602.
37. Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-685.
38. Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health. 2011;14(1):102-109.
39. Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford). 2008;47(2): 188-193.